The story has been updated to include Ariosa Diagnostics test in California's program.
NEW YORK (GenomeWeb News) – Illumina, Natera, and Ariosa Diagnostics today separately announced that their non-invasive prenatal screening tests for detecting fetal aneuploidies will be offered to women in California through the state's prenatal screening program.
Illumina said that starting today, the Verifi test, offered through its Verinata Health business, will be available to pregnant women who are at increased risk of carrying a fetus with trisomy 21 or trisomy 18, or who have had an ultrasound showing a large nuchal translucency.
Natera's Panorama test also is being offered through the California Prenatal Screening Program, which makes available to women serum screening for chromosomal abnormalities and neural tube defects. Those with a positive serum screen through the program have been able to receive follow-up services, including genetic counseling, ultrasound exam, amniocentesis, and chorionic villus sampling. NIPD testing, Natera said, is being added to the program as "an authorized reflex test" for expecting parents who have received a positive serum screening result for T21 or T18.
Additionally, Ariosa said that its Harmony Prenatal Test will be offered through the state's prenatal screening program.
The three company's tests will be offered through state-approved Prenatal Diagnosis Centers.